Novocure Hits Record Revenues and Expands Patient Reach—What’s Fueling This Growth?
Record 2025 Revenues Signal Strength Ahead of Key Clinical Milestones
Novocure (NASDAQ: NVCR) just reported an 8% year-over-year increase in 2025 net revenues, hitting a new high of $655.4 million. The company’s fourth-quarter revenues also met the 8% growth mark, totaling $174.4 million. These numbers point to robust demand for Novocure’s innovative Tumor Treating Fields (TTFields) therapies, setting up the company to capitalize on several important clinical and regulatory milestones in the coming year.
Global Active Patient Growth Surges Driven by Demand for Optune Gio
Driven by strong performance in its glioblastoma (GBM) franchise and the continued uptake of its Optune Lua device, the total number of active patients on TTFields therapy worldwide reached 4,620 at year-end—a jump of 12% compared to 2024. Notably, active Optune Gio patients rose 9% to 4,464, with the United States, Germany, France, and Japan showing the largest increases. This uptick comes as Novocure prepares for multiple product launches and regulatory submissions across major markets.
| Region | Optune Gio (2025) |
Optune Lua (2025) |
Total (2025) |
Optune Gio (2024) |
Optune Lua (2024) |
Total (2024) |
|---|---|---|---|---|---|---|
| United States | 2,251 | 110 | 2,361 | 2,161 | 31 | 2,192 |
| Germany | 623 | 43 | 666 | 564 | 11 | 575 |
| France | 509 | – | 509 | 426 | – | 426 |
| Japan | 542 | – | 542 | 420 | – | 420 |
| Other Intl. | 539 | 3 | 542 | 506 | 7 | 513 |
| Total | 4,464 | 156 | 4,620 | 4,077 | 49 | 4,126 |
Prescription Trends Show Expanding Use in Glioblastoma and Lung Cancer
Prescription volume for Optune Gio climbed 6% year-over-year to 1,609 in Q4, while active user numbers for Optune Gio in treatment of GBM rose notably across all core markets. Optune Lua, predominantly used for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), also showed gains: 118 prescriptions for NSCLC and 27 for MPM were recorded in the fourth quarter. The company reported 156 active Optune Lua patients at year end, up from 49 the prior year. Notably, the U.S. has led the uptick in new therapy adoption across both product lines.
Strategic Moves and Bright Outlook: Multiple Major Data Readouts Coming in 2026
Novocure enters 2026 with significant cash reserves of $448.3 million, even after paying off $561 million in convertible notes late last year. This puts the company in a strong position to execute new product launches and support ongoing trials. Noteworthy upcoming catalysts include:
- Topline data from the Phase 2 PANOVA-4 trial (metastatic pancreatic cancer) expected in Q1 2026
- Topline Phase 3 TRIDENT results (newly diagnosed GBM) coming in Q2 2026
- FDA decisions for TTFields in pancreatic cancer (Q2 2026) and brain metastases from NSCLC (Q4 2026)
- Completion of enrollment for Phase 3 KEYNOTE D58 trial (newly diagnosed GBM) in Q4 2026
Leadership changes in late 2025, including Frank Leonard’s appointment as CEO, could further accelerate these plans.
Key Takeaway: Growth Momentum, Financial Strength, and Major Readouts Ahead
Novocure’s record 2025 results highlight accelerating demand, broadening international adoption, and strong cash reserves to fuel the next growth chapter. With two pivotal clinical study readouts and multiple regulatory decisions set for 2026—not to mention a track record of patient growth—investors and industry watchers will be keeping a close eye on how the next phase plays out. The company’s shift away from reporting new prescription counts (for mature indications) will also focus attention directly on enduring patient volume and therapy expansion. With so many clinical readouts on the horizon, 2026 could prove decisive for Novocure’s market momentum and strategic direction.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI